Drugs / BF-200 ALA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05060237 | Dec 2021 → Apr 2023 | actinic keratosis, keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT01893203 | Aug 2013 → Dec 2014 | actinic keratosis | Joint Authority for Päijät-Häme Social and Health Care | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01966120 Comparator | Oct 2013 → Sep 2014 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02799082 Comparator | Dec 2007 → Oct 2008 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BF-200 ALA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060237 ↗ |
| Known as | Ameluz | “BF-200 ALA (Ameluz®)” NCT05060237 ↗ |
| Route | Topical | “a 0,25mm layer application of Ameluz cream on the area” NCT01893203 ↗ |